Cited by 2,051Cancer Immunotherapy and BiomarkersImmunotherapy and Immune ResponsesT-cell and B-cell Immunology

The DOI matches its Crossref record.

Cancer Immunotherapy

Couzin-Frankel, Jennifer·2013·Science

Open this paper in CoChat — free account

Abstract

This year marks a turning point in cancer, as long-sought efforts to unleash the immune system against tumors are paying off—even if the future remains a question mark.

Integrity signals

Registry

Crossref · 10.1126/science.342.6165.1432

Cites

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Sorted by citations

Items 201–300 of 1,000

Nanovaccines with cell-derived components for cancer immunotherapy
Meng, Z., Zhang, Y., Zhou, X., Ji, J., & Liu, Z. (2022) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2021.114107 · Cited by 126
Virus-like particle display of HER2 induces potent anti-cancer responses
Palladini, A., Thrane, S., Janitzek, C. M., Pihl, J., Clemmensen, S. B., de Jongh, W. A., Clausen, T. M., Nicoletti, G., Landuzzi, L., Penichet, M. L., et al. (2017) · OncoImmunology · doi:10.1080/2162402x.2017.1408749 · Cited by 124
Injectable hydrogels for the sustained delivery of a HER2-targeted antibody for preventing local relapse of HER2+ breast cancer after breast-conserving surgery
Chen, X., Wang, M., Yang, X., Wang, Y., Yu, L., Sun, J., & Ding, J. (2019) · Theranostics · doi:10.7150/thno.36514 · Cited by 126
Inorganic Nanoparticles Applied for Active Targeted Photodynamic Therapy of Breast Cancer
Montaseri, H., Kruger, C. A., & Abrahamse, H. (2021) · Pharmaceutics · doi:10.3390/pharmaceutics13030296 · Cited by 124
Acid‐Ionizable Iron Nanoadjuvant Augments STING Activation for Personalized Vaccination Immunotherapy of Cancer
Chen, F., Li, T., Zhang, H., Saeed, M., Liu, X., Huang, L., Wang, X., Gao, J., Hou, B., Lai, Y., et al. (2022) · Advanced Materials · doi:10.1002/adma.202209910 · Cited by 125
Increase in Both CD14-Positive and CD15-Positive Myeloid-Derived Suppressor Cell Subpopulations in the Blood of Patients With Glioma But Predominance of CD15-Positive Myeloid-Derived Suppressor Cells in Glioma Tissue
Gielen, P. R., Schulte, B. M., Kers‐Rebel, E. D., Verrijp, K. C. N., Petersen-Baltussen, H. M. J. M., ter Laan, M., Wesseling, P., & Adema, G. J. (2015) · Journal of Neuropathology & Experimental Neurology · doi:10.1097/nen.0000000000000183 · Cited by 117
Therapeutic In Situ Autovaccination against Solid Cancers with Intratumoral Poly-ICLC: Case Report, Hypothesis, and Clinical Trial
Salazar, A. Μ., Erlich, R. B., Mark, A. S., Bhardwaj, N., & Herberman, R. B. (2014) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-14-0024 · Cited by 122
A Cisplatin‐Loaded Immunochemotherapeutic Nanohybrid Bearing Immune Checkpoint Inhibitors for Enhanced Cervical Cancer Therapy
Wang, N., Wang, Z., Xu, Z., Chen, X., & Zhu, G. (2018) · Angewandte Chemie International Edition · doi:10.1002/anie.201800422 · Cited by 122
Discovery of Small-Molecule Inhibitors of the PD-1/PD-L1 Axis That Promote PD-L1 Internalization and Degradation
Wang, T., Cai, S., Cheng, Y., Zhang, W., Wang, M., Sun, H., Guo, B., Li, Z., Xiao, Y., & Jiang, S. (2022) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.1c01682 · Cited by 149
Recent Advances in Molecular Mechanisms of Cancer Immunotherapy
Kciuk, M., Yahya, E. B., Mohamed, M. M. I., Rashid, S., Iqbal, M. O., Kontek, R., Abdulsamad, M. A., & Allaq, A. A. (2023) · Cancers · doi:10.3390/cancers15102721 · Cited by 135
Immune checkpoints in cancer clinical trials
Sharon, E., STREICHER, H. Z., Goncalves, P. H., & Chen, H. X. (2014) · 癌症：英文版 · doi:10.5732/cjc.014.10122 · Cited by 121
Tumor-induced myeloid dysfunction and its implications for cancer immunotherapy
Messmer, M. N., Netherby, C. S., Banik, D., & Abrams, S. I. (2014) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-014-1639-3 · Cited by 121
Reactive Astrocytes in Brain Metastasis
Wasilewski, D., Priego, N., Torre, C. F., & Valiente, M. (2017) · Frontiers in Oncology · doi:10.3389/fonc.2017.00298 · Cited by 121
“Whilst brain metastasis remains a major threat to cancer patients, its annual incidence being on the rise, extracranial disease is becoming targeted more and more efficiently owing to the advent of molecular therapeutics as exemplified most recently by immune checkpoint inhibitors (112).”
Background
Abscopal Benefits of Localized Radiotherapy Depend on Activated T-cell Trafficking and Distribution between Metastatic Lesions
Poleszczuk, J., Luddy, K. A., Prokopiou, S., Robertson‐Tessi, M., Moros, E. G., Fishman, M., Djeu, J. Y., Finkelstein, S. E., & Enderling, H. (2016) · Cancer Research · doi:10.1158/0008-5472.can-15-1423 · Cited by 119
“7 2013 (5), is that novel immunotherapeutic strategies show remarkable responses in some patients, especially if combined with common cytotoxic agents.”
Background
Combination of Bacterial‐Photothermal Therapy with an Anti‐PD‐1 Peptide Depot for Enhanced Immunity against Advanced Cancer
Chen, W., Guo, Z., Zhu, Y., Qiao, N., Zhang, Z., & Sun, X. (2019) · Advanced Functional Materials · doi:10.1002/adfm.201906623 · Cited by 119
Visualization of Tumor-Immune Interaction - Target-Specific Imaging of S100A8/A9 Reveals Pre-Metastatic Niche Establishment
Eisenblätter, M., Flores‐Borja, F., Lee, J. J., Wefers, C., Smith, H. L., Hueting, R., Cooper, M. S., Blower, P. J., Patel, D., Rodriguez‐Justo, M., et al. (2017) · Theranostics · doi:10.7150/thno.17138 · Cited by 122
Fully automated sequential immunofluorescence (seqIF) for hyperplex spatial proteomics
Rivest, F., Eroglu, D., Pelz, B., Kowal, J., Kehren, A., Navikas, V., Procopio, M. G., Bordignon, P., Pérès, E., Ammann, M., et al. (2023) · Scientific Reports · doi:10.1038/s41598-023-43435-w · Cited by 130
Tapping CD4 T Cells for Cancer Immunotherapy: The Choice of Personalized Genomics
Zanetti, M. (2015) · The Journal of Immunology · doi:10.4049/jimmunol.1402669 · Cited by 133
The Complex Interplay between Chronic Inflammation, the Microbiome, and Cancer: Understanding Disease Progression and What We Can Do to Prevent It
Armstrong, H., Bording‐Jorgensen, M., Dijk, S., & Wine, E. (2018) · Cancers · doi:10.3390/cancers10030083 · Cited by 122
Dendritic Cell and T Cell Crosstalk in Liver Fibrogenesis and Hepatocarcinogenesis: Implications for Prevention and Therapy of Liver Cancer
Lurje, I., Hammerich, L., & Tacke, F. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21197378 · Cited by 118
“Honjo were jointly awarded the Nobel Prize in Physiology or Medicine for their discovery of negative immune regulation inhibition for cancer therapy [130,131].”
Background
Improving the safety of cell therapy with the TK-suicide gene
Greco, R., Oliveira, G., Stanghellini, M. T. L., Vago, L., Bondanza, A., Peccatori, J., Cieri, N., Marktel, S., Mastaglio, S., Bordignon, C., et al. (2015) · Frontiers in Pharmacology · doi:10.3389/fphar.2015.00095 · Cited by 122
Novel CD4-Based Bispecific Chimeric Antigen Receptor Designed for Enhanced Anti-HIV Potency and Absence of HIV Entry Receptor Activity
Liu, L., Patel, B., Ghanem, M. H., Bundoc, V., Zheng, Z., Morgan, R. A., Rosenberg, S. A., Dey, B., & Berger, E. A. (2015) · Journal of Virology · doi:10.1128/jvi.00474-15 · Cited by 121
Oxaliplatin-/NLG919 prodrugs-constructed liposomes for effective chemo-immunotherapy of colorectal cancer
Shen, F., Feng, L., Zhu, Y., Tao, D., Xu, J., Peng, R., & Liu, Z. (2020) · Biomaterials · doi:10.1016/j.biomaterials.2020.120190 · Cited by 118
Eliciting Immunogenic Cell Death via a Unitized Nanoinducer
Dai, Z., Tang, J., Gu, Z., Wang, Y., Yang, Y., Yang, Y., & Yu, C. (2020) · Nano Letters · doi:10.1021/acs.nanolett.0c00713 · Cited by 117
Multifunctional Nanodrug Mediates Synergistic Photodynamic Therapy and MDSCs‐Targeting Immunotherapy of Colon Cancer
Ding, D., Zhong, H., Liang, R., Lan, T., Zhu, X., Huang, S., Wang, Y., Shao, J., Shuai, X., & Wei, B. (2021) · Advanced Science · doi:10.1002/advs.202100712 · Cited by 117
Therapeutic use of anti-CTLA-4 antibodies
Blank, C. U., & Enk, A. (2014) · International Immunology · doi:10.1093/intimm/dxu076 · Cited by 115
Beyond the Role of CD55 as a Complement Component
Dho, S. H., Lim, J. C., & Kim, L. K. (2018) · Immune Network · doi:10.4110/in.2018.18.e11 · Cited by 115
“Most cancer immunotherapies are T cell modulatory therapies, including an immune checkpoint blockade that involves an anti-cytotoxic T-lymphocyte-associated protein 4 antibody (ipilimumab) and an anti-programmed cell death 1 antibody (pembrolizumab) as well as chimeric antigen receptor T cell therapy that modifies pat…”
Background
New emerging targets in cancer immunotherapy: the role of LAG3
Puhr, H. C., & Ilhan‐Mutlu, A. (2019) · ESMO Open · doi:10.1136/esmoopen-2018-000482 · Cited by 113
“TargeTed agenTs under developmenT Targeting cytotoxic T-lymphocyte-associated protein 4 (CTLA4) and PD1/PD-L1 axis induced clinically relevant objective response rates and extended overall and progression free survival in patients with several different tumour types.(32) 33 However, the majority of patients does not r…”
Background
Talkin’ Toxins: From Coley’s to Modern Cancer Immunotherapy
Carlson, R. D., Flickinger, J. C., & Snook, A. E. (2020) · Toxins · doi:10.3390/toxins12040241 · Cited by 131
Personalized Nanovaccine Coated with Calcinetin-Expressed Cancer Cell Membrane Antigen for Cancer Immunotherapy
Xiong, X., Zhao, J., Pan, J., Liu, C., Guo, X., & Zhou, S. (2021) · Nano Letters · doi:10.1021/acs.nanolett.1c03004 · Cited by 115
Trispecific natural killer cell nanoengagers for targeted chemoimmunotherapy
Au, K. M., Park, S. I., & Wang, A. Z. (2020) · Science Advances · doi:10.1126/sciadv.aba8564 · Cited by 113
Worldwide research trends on tumor burden and immunotherapy: a bibliometric analysis
Zhang, L., Zheng, H., Jiang, S., Liu, Y.-G., Zhang, T., Zhang, J., Lü, X., Zhao, H., Sang, X., & Xu, Y. (2024) · International Journal of Surgery · doi:10.1097/js9.0000000000001022 · Cited by 120
“Immunotherapy includes various concrete remedies: immune checkpoint inhibitors (ICI) [1 – 3] , CAR (chimeric antigens receptor) T-cell therapy [4,5] , cancer vaccines [6,7] , cytokines [8,9] , and oncolytic viruses [10] .”
Background
Programmed Death Ligand-1 Immunohistochemistry— A New Challenge for Pathologists: A Perspective From Members of the Pulmonary Pathology Society
Sholl, L. M., Aisner, D. L., Allen, T. C., Beasley, M. B., Borczuk, A., Cagle, P. T., Capelozzi, V. L., Đačić, S., Hariri, L. P., Kerr, K. M., et al. (2016) · Archives of Pathology & Laboratory Medicine · doi:10.5858/arpa.2015-0506-sa · Cited by 113
“The clinical benefit of this approach to cancer killing became clear when trials using antagonists against the T-cell regulator, CTLA4, such as ipilimumab, and subsequently PD-1, showed a survival benefit in patients with metastatic melanoma and led to remarkable response in a variety of solid tumors refractory to oth…”
Background
Targeting Toll-Like Receptors for Cancer Therapy
Braunstein, M. J., Kucharczyk, J. R., & Adams, S. (2018) · Targeted Oncology · doi:10.1007/s11523-018-0589-7 · Cited by 114
Development of Inhibitors of the Programmed Cell Death-1/Programmed Cell Death-Ligand 1 Signaling Pathway
Wang, T., Wu, X., Guo, C., Zhang, K., Xu, J., Li, Z., & Jiang, S. (2018) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.8b00990 · Cited by 119
Molecular Recognition of Gangliosides and Their Potential for Cancer Immunotherapies
Krengel, U., & Bousquet, P. A. (2014) · Frontiers in Immunology · doi:10.3389/fimmu.2014.00325 · Cited by 111
“There are two main approaches (139, 140): (i) tumor-associated antigens or derivatives or mimics of these may be used as active therapeutic vaccines, priming the body to launch an immune attack against these molecules and hence the tumor cells (overcoming the body’s tolerance of self-antigens); (ii) alternatively, ant…”
Background
Prussian blue nanoparticles: Synthesis, surface modification, and application in cancer treatment
Gautam, M., Poudel, K., Yong, C. S., & Kim, J. O. (2018) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2018.07.055 · Cited by 110
A human CD137×PD-L1 bispecific antibody promotes anti-tumor immunity via context-dependent T cell costimulation and checkpoint blockade
Geuijen, C. A. W., Tacken, P. J., Wang, L.-C., Klooster, R., van Loo, P. F., Zhou, J., Mondal, A., Liu, Y.-B., Kramer, A., Condamine, T., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-24767-5 · Cited by 114
An FDA oncology analysis of CD3 bispecific constructs and first-in-human dose selection
Saber, H., Valle, P. D., Ricks, T. K., & Leighton, J. K. (2017) · Regulatory Toxicology and Pharmacology · doi:10.1016/j.yrtph.2017.09.001 · Cited by 108
Cancer Immunotherapy: A Focus on the Regulation of Immune Checkpoints
Shi, T., Ma, Y., Yu, L., Jiang, J., Shen, S., Hou, Y., & Wang, T. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19051389 · Cited by 112
Circular Bispecific Aptamer-Mediated Artificial Intercellular Recognition for Targeted T Cell Immunotherapy
Yang, Y. P., Sun, X., Xu, J., Cui, C., Yazd, H. S., Pan, X., Zhu, Y., Chen, X., Li, X., Li, J., et al. (2020) · ACS Nano · doi:10.1021/acsnano.9b09884 · Cited by 112
Extracellular Vesicles Present in Human Ovarian Tumor Microenvironments Induce a Phosphatidylserine-Dependent Arrest in the T-cell Signaling Cascade
Kelleher, R. J., Balu‐Iyer, S. V., Loyall, J. L., Sacca, A. J., Shenoy, G. N., Peng, P., Iyer, V., Fathallah, A. M., Berenson, C. S., Wallace, P. K., et al. (2015) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-15-0086 · Cited by 109
The hepatitis B virus-associated tumor microenvironment in hepatocellular carcinoma
Yang, P., Markowitz, G. J., & Wang, X. (2014) · National Science Review · doi:10.1093/nsr/nwu038 · Cited by 112
“Promotion of a robust antitumor immune response indeed is perhaps the most desirable outcome: the remarkable efficacy of T-cell immunotherapy through either engineering (chimeric antigen receptor therapy) or relieving the brakes on T-cell activity (anti-PD-1, anti-PD-L1, and anti-CTLA-4, which block interactions betwe…”
Background
Immunotherapy in hematologic malignancies: past, present, and future
Im, A., & Pavletic, S. Z. (2017) · Journal of Hematology & Oncology · doi:10.1186/s13045-017-0453-8 · Cited by 112
The development of bispecific antibodies and their applications in tumor immune escape
Zhang, X., Yang, Y., Fan, D., & Xiong, D. (2017) · Experimental Hematology and Oncology · doi:10.1186/s40164-017-0072-7 · Cited by 112
Advanced smart-photosensitizers for more effective cancer treatment
Park, W., Cho, S., Han, J., Shin, H., Na, K., Lee, B., & Kim, D. (2017) · Biomaterials Science · doi:10.1039/c7bm00872d · Cited by 111
Intradermal vaccination using the novel microneedle device MicronJet600: Past, present, and future
Levin, Y., Kochba, E., Hung, I. F., & Kenney, R. T. (2015) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2015.1010871 · Cited by 110
PD-1, PD-L1 (B7-H1) and Tumor-Site Immune Modulation Therapy: The Historical Perspective
Wang, J., Yuan, R., Song, W., Sun, J., Liu, D., & Li, Z. (2017) · Journal of Hematology & Oncology · doi:10.1186/s13045-017-0403-5 · Cited by 111
Nucleic Acid–Based Functional Nanomaterials as Advanced Cancer Therapeutics
Yuan, Y., Gu, Z., Yao, C., Luo, D., & Yang, D. (2019) · Small · doi:10.1002/smll.201900172 · Cited by 108
Recent progress on third generation covalent EGFR inhibitors
Cheng, H., Nair, S. K., & Murray, B. W. (2016) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2016.02.067 · Cited by 110
Combining radiotherapy with immunotherapy: the past, the present and the future
Limbergen, E. J. V., Ruysscher, D. D., Pimentel, V. O., Marcus, D., Berbée, M., Hoeben, A., Rekers, N. H., Theys, J., Yaromina, A., Dubois, L. J., et al. (2017) · British Journal of Radiology · doi:10.1259/bjr.20170157 · Cited by 105
“The following period was a rollercoaster of clinical successes, with immunotherapy being declared the scientific breakthrough of the year in 2013 by the Science magazine.(18) During this period, two case reports were Figure 1.”
Background
Photothermal therapy-induced immunogenic cell death based on natural melanin nanoparticles against breast cancer
Li, Y., Liu, X., Pan, W., Li, N., & Tang, B. (2019) · Chemical Communications · doi:10.1039/c9cc08447a · Cited by 104
An Update on Neurofibromatosis Type 1-Associated Gliomas
Lobbous, M., Bernstock, J. D., Coffee, E., Friedman, G. K., Metrock, L. K., Chagoya, G., Elsayed, G., Nakano, I., Hackney, J. R., Korf, B. R., et al. (2020) · Cancers · doi:10.3390/cancers12010114 · Cited by 111
Immune checkpoints and rheumatic diseases: what can cancer immunotherapy teach us?
van der Vlist, M., Kuball, J. H. E., Radstake, T. R. D. J., & Meyaard, L. (2016) · Nature Reviews Rheumatology · doi:10.1038/nrrheum.2016.131 · Cited by 102
“The potential of the immune checkpoints as thera‑ peutic targets is well‑illustrated by recent advances in cancer therapy: immune checkpoint blockade ther‑ apy to overcome immune tolerance to malignant cells was selected as “Breakthrough of the Year 2013” by Science magazine 8 (reviewed in REF.”
Local Phototherapy Synergizes with Immunoadjuvant for Treatment of Pancreatic Cancer through Induced Immunogenic Tumor Vaccine
Zhou, F., Yang, J., Zhang, Y., Liu, M., Lang, M. L., Li, M., & Chen, W. R. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-1126 · Cited by 98
Targeting innate sensing in the tumor microenvironment to improve immunotherapy
Liu, Z., Han, C., & Fu, Y. (2019) · Cellular and Molecular Immunology · doi:10.1038/s41423-019-0341-y · Cited by 105
Nanoliposomes as the adjuvant delivery systems in cancer immunotherapy
Zamani, P., Momtazi‐Borojeni, A. A., Nik, M. E., Oskuee, R. K., & Sahebkar, A. (2017) · Journal of Cellular Physiology · doi:10.1002/jcp.26361 · Cited by 101
“The main therapeutic approaches for cancer therapy are the conventional methods such as surgery, radiation therapy, and chemotherapy (Wu et al., 2014), which are known to be associated with severe side effects and toxicity on thenormal cells (Couzin-Frankel, 2013).”
Method
Harnessing cancer immunotherapy during the unexploited immediate perioperative period
Matzner, P., Sandbank, E., Neeman, E., Zmora, O., Gottumukkala, V. N. R., & Ben‐Eliyahu, S. (2020) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-019-0319-9 · Cited by 104
Advances in personalized cancer immunotherapy
Kakimi, K., Karasaki, T., Matsushita, H., & Sugie, T. (2016) · Breast Cancer · doi:10.1007/s12282-016-0688-1 · Cited by 103
OX40 Agonist BMS-986178 Alone or in Combination With Nivolumab and/or Ipilimumab in Patients With Advanced Solid Tumors
Gutierrez, M. E., Moreno, V., Heinhuis, K. M., Olszanski, A. J., Spreafico, A., Ong, M., Chu, Q. S.-C., Carvajal, R. D., Trigo, J. M., Ochoa-de-Olza, M., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-1830 · Cited by 102
“Despite these benefits, many patients exhibit resistance to checkpoint inhibitor therapies (3).”
Background
Efficiency of Conditionally Attenuated Salmonella enterica Serovar Typhimurium in Bacterium-Mediated Tumor Therapy
Frahm, M., Felgner, S., Kocijancic, D., Rohde, M., Hensel, M., Curtiss, R., Erhardt, M., & Weiß, S. (2015) · mBio · doi:10.1128/mbio.00254-15 · Cited by 103
Prospects for chimeric antigen receptor-modified T cell therapy for solid tumors
Zhang, E., Gu, J., & Xu, H. (2018) · Molecular Cancer · doi:10.1186/s12943-018-0759-3 · Cited by 103
Polymeric microparticles for sustained and local delivery of antiCD40 and antiCTLA-4 in immunotherapy of cancer
Rahimian, S., Fransen, M. F., Kleinovink, J. W., Amidi, M., OSSENDORP, F. A., & Hennink, W. E. (2015) · Biomaterials · doi:10.1016/j.biomaterials.2015.04.043 · Cited by 100
Potent suppression of neuroendocrine tumors and gastrointestinal cancers by CDH17CAR T cells without toxicity to normal tissues
Feng, Z., He, X., Zhang, X., Wu, Y., Xing, B., Knowles, A., Shan, Q., Miller, S. I., Hojnacki, T., Ma, J., et al. (2022) · Nature Cancer · doi:10.1038/s43018-022-00344-7 · Cited by 101
Immune Checkpoint Modulation for Non–Small Cell Lung Cancer
Soria, J., Marabelle, A., Brahmer, J. R., & Gettinger, S. N. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-2959 · Cited by 102
“The translation of this strategy into patientswith lung cancer has been fruitful, with durable responses in some patients with advanced disease who would otherwise have limited systemic options for treatment of their cancer (11).”
Background
Phytosomal curcumin causes natural killer cell-dependent repolarization of glioblastoma (GBM) tumor-associated microglia/macrophages and elimination of GBM and GBM stem cells
Mukherjee, S., Fried, A., Hussaini, R., White, R., Baidoo, J., Yalamanchi, S., & Banerjee, P. (2018) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-018-0792-5 · Cited by 100
The Human Immunopeptidome Project: A Roadmap to Predict and Treat Immune Diseases
Vizcaíno, J. A., Kubiniok, P., Kovalchik, K. A., Ma, Q., Duquette, J. D., Mongrain, I., Deutsch, E. W., Peters, B., Sette, A., Sirois, I., et al. (2019) · Molecular & Cellular Proteomics · doi:10.1074/mcp.r119.001743 · Cited by 93
Tumor microenvironment-responsive prodrug nanoplatform via co-self-assembly of photothermal agent and IDO inhibitor for enhanced tumor penetration and cancer immunotherapy
Liu, Y., Lu, Y., Zhu, X., Li, C., Yan, M., Pan, J., & Ma, G. (2020) · Biomaterials · doi:10.1016/j.biomaterials.2020.119933 · Cited by 99
Small-Molecule Immune Checkpoint Inhibitors Targeting PD-1/PD-L1 and Other Emerging Checkpoint Pathways
Sasikumar, P. G., & Ramachandra, M. (2018) · BioDrugs · doi:10.1007/s40259-018-0303-4 · Cited by 99
Disrupting LILRB4/APOE Interaction by an Efficacious Humanized Antibody Reverses T-cell Suppression and Blocks AML Development
Gui, X., Deng, M., Song, H., Chen, Y., Xie, J., Li, Z., He, L., Huang, F., Xu, Y., Anami, Y., et al. (2019) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-19-0036 · Cited by 99
Clostridium butyricum therapy restores the decreased efficacy of immune checkpoint blockade in lung cancer patients receiving proton pump inhibitors
Tomita, Y., Goto, Y., Sakata, S., Imamura, K., Minemura, A., Oka, K., Hayashi, A., Jodai, T., Akaike, K., Anai, M., et al. (2022) · OncoImmunology · doi:10.1080/2162402x.2022.2081010 · Cited by 100
Exosomal PD‐L1: New Insights Into Tumor Immune Escape Mechanisms and Therapeutic Strategies
Zhou, K., Guo, S., Li, F., Sun, Q., & Liang, G. (2020) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2020.569219 · Cited by 99
“Therefore, anti-PD-1/PD-L1 inhibitors are able to induce durable tumor regression and represent a unique therapeutic strategy for patients with advanced cancers (Couzin-Frankel, 2013; Mahoney et al., 2015; Ribas et al., 2016; Yaghoubi et al., 2019).”
Background
Delivery of therapeutics with nanoparticles: what's new in cancer immunotherapy?
Fontana, F., Liu, D., Hirvonen, J. J., & Santos, H. A. (2016) · Wiley Interdisciplinary Reviews Nanomedicine and Nanobiotechnology · doi:10.1002/wnan.1421 · Cited by 98
Lymphotoxin signalling in tertiary lymphoid structures and immunotherapy
Tang, H., Zhu, M., Qiao, J., & Fu, Y. (2017) · Cellular and Molecular Immunology · doi:10.1038/cmi.2017.13 · Cited by 97
Peptide-based and small synthetic molecule inhibitors on PD-1/PD-L1 pathway: A new choice for immunotherapy?
Chen, T., Li, Q., Liu, Z., Chen, Y., Feng, F., & Sun, H. (2018) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2018.10.044 · Cited by 100
The ReNAissanCe of mRNA-based cancer therapy
Van Lint, S., Renmans, D., Broos, K., Dewitte, H., Lentacker, I., Heirman, C., Breckpot, K., & Thielemans, K. (2015) · Expert Review of Vaccines · doi:10.1586/14760584.2015.957685 · Cited by 95
“Harnessing the patient’s immune system to combat tumors, referred to as cancer immunotherapy, has proven to be a challenging endeavor that only recently started to deliver on its promise [8].”
Background
Fever‐Inspired Immunotherapy Based on Photothermal CpG Nanotherapeutics: The Critical Role of Mild Heat in Regulating Tumor Microenvironment
Li, Y., He, L., Dong, H., Liu, Y., Wang, K., Li, A., Ren, T., Shi, D., & Li, Y. (2018) · Advanced Science · doi:10.1002/advs.201700805 · Cited by 95
Molecular landscape of esophageal cancer: implications for early detection and personalized therapy
Talukdar, F. R., di Pietro, M., Secrier, M., Moehler, M. H., Goepfert, K., Soares‐Lima, S. C., Pinto, L. F. R., Hendricks, D. T., Parker, M. I., & Herceg, Z. (2018) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.13876 · Cited by 96
Affinity purification mass spectrometry analysis of PD-1 uncovers SAP as a new checkpoint inhibitor
Peled, M., Tocheva, A. S., Sandigursky, S., Nayak, S., Philips, E. A., Nichols, K. E., Strazza, M., Azoulay-Alfaguter, I., Askenazi, M., Neel, B. G., et al. (2018) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1710437115 · Cited by 87
“PD-1 has recently drawn attention because of the clinical efficacy of blocking the PD-1 pathway in cancer immunotherapy (17, 18).”
Background
Universes Collide: Combining Immunotherapy with Targeted Therapy for Cancer
Wargo, J. A., Cooper, Z. A., & Flaherty, K. T. (2014) · Cancer Discovery · doi:10.1158/2159-8290.cd-14-0477 · Cited by 94
“Another form of immunotherapy receiving recent “breakthrough” status for the treatment of melanoma and other cancers involves the use of immune checkpoint inhibitors (33).”
Chimeric Antigen Receptors: A Cell and Gene Therapy Perspective
Rivière, I., & Sadelain, M. (2017) · Molecular Therapy · doi:10.1016/j.ymthe.2017.03.034 · Cited by 96
Cancer-Associated Angiogenesis: The Endothelial Cell as a Checkpoint for Immunological Patrolling
Solimando, A. G., Summa, S. D., Vacca, A., & Ribatti, D. (2020) · Cancers · doi:10.3390/cancers12113380 · Cited by 93
An orally available PD-1/PD-L1 blocking peptide OPBP-1-loaded trimethyl chitosan hydrogel for cancer immunotherapy
Li, W., Zhu, X., Zhou, X., Wang, X., Zhai, W., Li, B., Du, J., Li, G., Sui, X., Wu, Y., et al. (2021) · Journal of Controlled Release · doi:10.1016/j.jconrel.2021.04.036 · Cited by 96
Engineered Living Materials for Advanced Diseases Therapy
Xue, D. Q., Wu, W. H., Pan, P., & Zhang, X. (2023) · Advanced Materials · doi:10.1002/adma.202304963 · Cited by 95
ATP‐Responsive Manganese‐Based Bacterial Materials Synergistically Activate the cGAS‐STING Pathway for Tumor Immunotherapy
Huang, Y., Yang, S., Guo, Q., Sheng, J., & Mao, Z. (2024) · Advanced Materials · doi:10.1002/adma.202310189 · Cited by 95
Antibody-cytokine fusion proteins: Biopharmaceuticals with immunomodulatory properties for cancer therapy
Hutmacher, C., & Neri, D. (2018) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2018.09.002 · Cited by 94
Current modalities in cancer immunotherapy: Immunomodulatory antibodies, CARs and vaccines
Lohmueller, J. J., & Finn, O. J. (2017) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2017.03.008 · Cited by 96
Double enhancement of immunogenic cell death and antigen presentation for cancer immunotherapy
Xiong, X., Zhao, J., Su, R., Liu, C., Guo, X., & Zhou, S. (2021) · Nano Today · doi:10.1016/j.nantod.2021.101225 · Cited by 94
Personalized T cell-mediated cancer immunotherapy: progress and challenges
Bethune, M. T., & Joglekar, A. V. (2017) · Current Opinion in Biotechnology · doi:10.1016/j.copbio.2017.03.024 · Cited by 91
“Cancer immunotherapies exploiting this capacity constitute a paradigm shift in cancer treatment, yielding successes where conventional cancer therapies fail [16].”
Background
N6-Methyladenosine modification: a novel pharmacological target for anti-cancer drug development
Niu, Y., Wan, A. H., Lin, Z., Lu, X., & Wan, G. (2018) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2018.06.001 · Cited by 90
A novel cyclic peptide targeting LAG-3 for cancer immunotherapy by activating antigen-specific CD8+ T cell responses
Zhai, W., Zhou, X., Wang, H., Li, W., Chen, G., Sui, X., Li, G., Qi, Y., & Gao, Y. (2020) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2020.01.005 · Cited by 93
Cancer photo-immunotherapy: from bench to bedside
Wang, M., Rao, J., Wang, M., Li, X., Liu, K., Naylor, M. F., Nordquist, R. E., Chen, W. R., & Zhou, F. (2020) · Theranostics · doi:10.7150/thno.53056 · Cited by 91
FOXO1 opposition of CD8 + T cell effector programming confers early memory properties and phenotypic diversity
Delpoux, A., Lai, C.-Y., Hedrick, S. Μ., & Doedens, A. L. (2017) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1618916114 · Cited by 92
“memory programming of CD8 T cells is of intense basic and applied research interest (2, 33).”
Background
Combined drug therapeutic strategies for the effective treatment of Triple Negative Breast Cancer
Chalakur-Ramireddy, N. K. R., & Pakala, S. B. (2018) · Bioscience Reports · doi:10.1042/bsr20171357 · Cited by 89
Nanotechnologies for biomedical science and translational medicine
Heath, J. R. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1515202112 · Cited by 93
Concurrent, but not sequential, PD-1 blockade with a DNA vaccine elicits anti-tumor responses in patients with metastatic, castration-resistant prostate cancer
McNeel, D. G., Eickhoff, J. C., Wargowski, E., Zahm, C. D., Staab, M. J., Straus, J., & Liu, G. (2018) · Oncotarget · doi:10.18632/oncotarget.25387 · Cited by 89
Exploiting the Immunomodulatory Properties of Chemotherapeutic Drugs to Improve the Success of Cancer Immunotherapy
Kersten, K., Salvagno, C., & de Visser, K. E. (2015) · Frontiers in Immunology · doi:10.3389/fimmu.2015.00516 · Cited by 92
Surgical Stress Abrogates Pre-Existing Protective T Cell Mediated Anti-Tumor Immunity Leading to Postoperative Cancer Recurrence
Ananth, A. A., Tai, L., Lansdell, C., Alkayyal, A. A., Baxter, K. E., Angka, L., Zhang, J., de Souza, C. T., Stephenson, K. B., Parato, K. A., et al. (2016) · PLoS ONE · doi:10.1371/journal.pone.0155947 · Cited by 91
Immune Conversion of Tumor Microenvironment by Oncolytic Viruses: The Protoparvovirus H-1PV Case Study
Marchini, A., Daeffler, L., Pozdeev, V. I., Angelova, A. L., & Rommelaere, J. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.01848 · Cited by 95
OX40 (CD134) and OX40 ligand, important immune checkpoints in cancer
Deng, J., Zhao, S., Zhang, X., Jia, K., Wang, H., Zhou, C., & He, Y. (2019) · OncoTargets and Therapy · doi:10.2147/ott.s214211 · Cited by 91

Authors: Couzin-Frankel, J.
Corresponding author: Couzin-Frankel, Jennifer
Venue: Science
Publisher: American Association for the Advancement of Science (AAAS)
Published: 2013-12-20
Volume: 342
Issue: 6165
Pages: 1432-1433
ISSN: 0036-8075 (ISSN-L)
1095-9203
DOI: 10.1126/science.342.6165.1432
OpenAlex: W2209812019
Cited by: 2,051
References: 0
Citations by year: 2026: 34 · 2025: 100 · 2024: 133 · 2023: 154 · 2022: 172 · 2021: 215 · 2020: 220 · 2019: 197 · 2018: 206 · 2017: 206 · 2016: 138 · 2015: 169 · 2014: 103 · 2013: 2
FWCI: 73.49
Type: journal article
Language: en
Open access: closed
Locations: Science (publishedVersion)
PubMed (publishedVersion)
Topics: Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
Keywords: cancer immunotherapy, tumor immunology, immune checkpoint inhibitors
MeSH terms: Ipilimumab, Antibodies, Antibodies, Monoclonal, Clinical Trials as Topic, Humans, Immunotherapy, Melanoma, Neoplasms, T-Lymphocytes, CTLA-4 Antigen

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Cancer Immunotherapy

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cited by

Related

Metadata

Record

About these checks